Burden hours
readjusted to capture both recordkeeping and reporting burden
hours. In future submissions, agency must itemize and explain in
the supporting statement the source of any recordkeeping,
reporting, and disclosure burden hours.
Inventory as of this Action
Requested
Previously Approved
10/31/2011
6 Months From Approved
119
0
0
4,760
0
0
0
0
0
This revenue procedure establishes a
dispute resolution process for the preliminary fee calculation for
the 2011 annual fee imposed on covered entities engaged in the
business of manufacturing or importing branded prescription drugs.
The fee was enacted by section 9008 of the Patient Protection and
Affordable Care Act (ACA), Public Law 111-148 (124 Stat. 119
(2010)), as amended by section 1404 of the Health Care and
Education Reconciliation Act of 2010 (HCERA), Public Law 111-152
(124 Stat. 1029 (2010)). All references in this revenue procedure
to section 9008 are references to section 9008 of the ACA, as
amended by section 1404 of HCERA.
Affordable Care Act
[PPACA, P.L. 111-148 & 111-152]. The reason for this emergency
submission is to provide as soon as possible a covered entity with
a dispute resolution process for a fee that the covered entity must
pay by September 30, 2011. By May 16, 2011, the IRS will provide a
covered entity with a preliminary fee calculation. If a covered
entity disputes the IRS preliminary fee calculation, the covered
entity must submit, as described in section 4.01 of the proposed
revenue procedure, an error report, postmarked by June 1, 2011, to
the IRS. A covered entity must include in its error report an
explanation of the error and the data to substantiate the claimed
error. The IRS must resolve fee disputes by July 15, 2011, in order
to provide a covered entity with a final fee determination by
August 15, 2011.
PL: Pub.L. 111 - 148 9008 Name of Law:
Affordable Care Act (ACA)
PL: Pub.L. 111 - 152 1404 Name of Law: Health Care and Education
Reconciliation Act of 2010 (HCERA)
This revenue procedure
establishes a dispute resolution process for the preliminary fee
calculation for the 2011 annual fee imposed on covered entities
engaged in the business of manufacturing or importing branded
prescription drugs. This is a new collection related to the Patient
Protection and Affordable Care Act (ACA). As a result of this new
collection, we estimate the number of new responses of 119 and
estimated total burden increase of 4,760 hours.
$0
No
No
Yes
No
No
Uncollected
Celia Gabrysh 202
622-3130
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.
Draft BPD Dispute Resolution RevProc April 4.doc
RP-108248-11, Branded Prescription Drug Sales Dispute Resolution Process for 2011 Preliminary Fee Calculation